litlas
Log inCreate account

Yoshihiko Tomita

Active 1990–2025

96
Papers
22,093
Citations
50
h-index
87
i10-index

Citations

Citations per year for Yoshihiko Tomita1992: 2 citations1993: 2 citations1995: 2 citations1996: 4 citations1997: 2 citations1998: 3 citations1999: 4 citations2000: 6 citations2001: 14 citations2002: 8 citations2003: 2 citations2004: 17 citations2005: 12 citations2006: 15 citations2007: 14 citations2008: 19 citations2009: 9 citations2010: 11 citations2011: 19 citations2012: 25 citations2013: 34 citations2014: 21 citations2015: 23 citations2016: 178 citations2017: 206 citations2018: 273 citations2019: 897 citations2020: 1,104 citations2021: 1,119 citations2022: 963 citations2023: 737 citations2024: 1,269 citations2025: 551 citations2026: 9 citations1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,274 citing papers, 22.9% of this breakdownChina: 1,081 citing papers, 10.9% of this breakdownItaly: 617 citing papers, 6.2% of this breakdownJapan: 604 citing papers, 6.1% of this breakdownFrance: 568 citing papers, 5.7% of this breakdownUnited Kingdom: 555 citing papers, 5.6% of this breakdownGermany: 443 citing papers, 4.4% of this breakdownSpain: 398 citing papers, 4% of this breakdownCanada: 367 citing papers, 3.7% of this breakdownNetherlands: 253 citing papers, 2.5% of this breakdownAustralia: 249 citing papers, 2.5% of this breakdownSouth Korea: 193 citing papers, 1.9% of this breakdown
0%22.9%Other 23.6%

Institutions

Fields

  • Medicine82%
  • Biochemistry, Genetics and Molecular Biology10.7%
  • Immunology and Microbiology4.8%
  • Engineering0.8%
  • Neuroscience0.3%
  • Economics, Econometrics and Finance0.2%
  • Other1.2%

Topics

  • Cancer Immunotherapy and Biomarkers19%
  • Renal cell carcinoma treatment9.2%
  • Bladder and Urothelial Cancer Treatments4.8%
  • Immunotherapy and Immune Responses4.4%
  • Ferroptosis and cancer prognosis4.1%
  • CAR-T cell therapy research3.7%
  • Other54.8%

Coauthors

All papers

Open in search
  1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 cited by 4,643

  2. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma - New England Journal of Medicine 2015 cited by 5,890

  3. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C. Goh, Carlos H. Barrios, Martin Eduardo Richardet, Camillo Porta, Rubén Dario Kowalyszyn, Juan P. Feregrino, Jakub Żołnierek, David Pook, Elizabeth R. Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew Maurer, Burçin Şimşek, Flavia Ejzykowicz, Gisela Schwab, Andrea B. Apolo, Robert J. Motzer - New England Journal of Medicine 2021 cited by 1,746

  4. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

    Authors: Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Dingwei Ye, Mads Agerbæk, Deborah Enting, Ray McDermott, Pablo Gajate, Avivit Peer, Matthew I. Milowsky, А. К. Носов, João Neif Antonio, Krzysztof Tupikowski, Laurence Toms, Bruce S. Fischer, Anila Qureshi, Sandra Collette, Keziban Ünsal-Kaçmaz, Edward Broughton, Dimitrios Zardavas, Henry Koon, Matthew D. Galsky - New England Journal of Medicine 2021 cited by 1,031

  5. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

    Authors: Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Gurkamal Chatta, Yüksel Ürün, Dingwei Ye, Zhisong He, Begoña P. Valderrama, Ja Hyeon Ku, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, M. PATEL, Federico Nasroulah, Matthew D. Galsky - New England Journal of Medicine 2023 cited by 462

  6. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Authors: Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir - Cancer 2022 cited by 263

  7. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

    Authors: Robert J. Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher Hocking, Elizabeth R. Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burçin Şimşek, Christian Scheffold, Andrea B. Apolo, Toni K. Choueiri - The Lancet Oncology 2022 cited by 307

  8. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

    Authors: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, Shruti Shally Saggi, M. Brent McHenry, Robert J. Motzer - ESMO Open 2020 cited by 522

  9. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Authors: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 cited by 780

  10. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

    Authors: Sumanta K. Pal, Robert G. Uzzo, José A. Karam, Viraj A. Master, Frede Donskov, Cristina Suárez, Laurence Albigès, Brian I. Rini, Yoshihiko Tomita, Ariel Galapo Kann, Giuseppe Procopio, Francesco Massari, Matthew R. Zibelman, I. Antonyan, Mahrukh Huseni, Debasmita Basu, Bo Ci, William Leung, Omara Khan, Sarita Dubey, Axel Bex - The Lancet 2022 cited by 230

  11. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    Authors: Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Cancer 2020 cited by 337

  12. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

    Authors: Robert J. Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Żurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean‐Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey A. Sosman, Michael Staehler, Sergio Vázquez Estévez, Burçin Şimşek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex - The Lancet 2023 cited by 172

  13. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

    Authors: Nizar M. Tannir, Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Sangeeth M. George, Frede Donskov, Michael B. Atkins, Howard Gurney, C.K. Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, Ruowei Jiang, Heshani Desilva, В. Э. Федоров, Chung‐Wei Lee, Robert J. Motzer - Annals of Oncology 2024 cited by 192

  14. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

    Authors: Robert J. Motzer, Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R. Plimack, Philippe Barthélémy, Hans J. Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K. Choueiri, Brian I. Rini, Pamela Salman, Christian Kollmannsberger, Scott S. Tykodi, Marc‐Oliver Grimm, Howard Gurney, Raya Leibowitz‐Amit, Poul Geertsen, Asim Amin, Yoshihiko Tomita, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Journal for ImmunoTherapy of Cancer 2020 cited by 225

  15. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

    Authors: Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, P. Wang, В. Э. Федоров, Robert J. Motzer, Toni K. Choueiri - ESMO Open 2024 cited by 91

  16. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.

    Authors: Nizar M. Tannir, Bernard Escudier, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Michael B. Atkins, Christian Kollmannsberger, Marc‐Oliver Grimm, Yoshihiko Tomita, Brian I. Rini, Ruiyun Jiang, Heshani Desilva, Chung‐Wei Lee, Robert J. Motzer - Journal of Clinical Oncology 2024 cited by 46

  17. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

    Authors: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, David Leung, Shruti Shally Saggi, Chung‐Wei Lee, M. Brent McHenry, Robert J. Motzer - European Urology 2021 cited by 80

  18. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

    Authors: Toni K. Choueiri, James Larkin, Mototsugu Oya, Fiona Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David F. McDermott, Paul B. Robbins, David D. Chism, Daniel Cho, Michael B. Atkins, Michael S. Gordon, Sumati Gupta, Hirotsugu Uemura, Yoshihiko Tomita, Anna Compagnoni, Camilla Fowst, Alessandra di Pietro, Brian I. Rini - The Lancet Oncology 2018 cited by 260

  19. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

    Authors: Mauricio Burotto, Thomas Powles, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, Peter Wang, Viktor Fedorov, Robert J. Motzer, Toni K. Choueiri - Journal of Clinical Oncology 2023 cited by 47

  20. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

    Authors: Matthew D. Galsky, J. Alfred Witjes, Jürgen E. Gschwend, Matthew I. Milowsky, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Mads Agerbæk, Gautam Jha, Frank Stenner, Dingwei Ye, Fabio Giudici, Santanu Dutta, Margarita Askelson, Federico Nasroulah, Joshua Zhang, Lynne Brophy, Dean F. Bajorin - Journal of Clinical Oncology 2024 cited by 99

  21. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

    Authors: Yoshihiko Tomita, Robert J. Motzer, Toni K. Choueiri, Brian I. Rini, Hideaki Miyake, Hirotsugu Uemura, Laurence Albigès, Yoshiro Fujii, Yoshiko Umeyama, J Wang, Mariangela Mariani, Manuela Schmidinger - ESMO Open 2022 cited by 51

  22. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

    Authors: Daniel P. Petrylak, Ronald de Wit, Kim N., Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aude Fléchon, Aristotelis Bamias, Evan Y. Yu, Michiel S. van der Heijden, Nobuaki Matsubara, B. Yа. Alekseev, Andrea Necchi, Lajos Géczi, Yen-Chuan Ou, Hasan Şenol Çoşkun, Wen‐Pin Su, Jens Bedke, Georgios Gakis, Ivor Percent, Jae‐Lyun Lee, Marcello Tucci, Andrey Semenov, Fredrik Laestadius, Avivit Peer, Giampaolo Tortora, Sufia Safina, Xavier García del Muro, Alejo Rodríguez‐Vida, İrfan Çiçin, Hakan Harputluoğlu, Scott T. Tagawa, Ulka N. Vaishampayan, Jeanny B. Aragon‐Ching, Oday Hamid, Astra M. Liepa, Sameera R. Wijayawardana, Francesca Russo, Richard A. Walgren, Annamaria H. Zimmermann, Rebecca R. Hozak, Katherine M. Bell‐McGuinn, Thomas Powles, Suet-Lai Shirley Wong, Thean Hsiang Tan, Elizabeth Hovey, Timothy Clay, Siobhan Ng, Annemie Rutten, Jean-Pascal Machiels, Herlinde Dumez, Susanna Y. Cheng, Cristiano Ferrario, Lisa Sengeloev, Niels Viggo Jensen, Constance Thibault, Brigitte Laguerre, Florence Joly, Stéphane Culine, Catherine Becht, Günter Niegisch, Michael Stöckle, Marc‐Oliver Grimm, Christina A Schwentner, Wolfgang Schultze‐Seemann, Haralambos Kalofonos, Dimitriοs Mavroudis, Christos N. Papandreou, Vasilis Karavasilis, János Révész, Eli Rosenbaum, Raya Leibowitz‐Amit, Daniel Kejzman, David Sarid, Giorgio V. Scagliotti, Sergio Bracarda, Francesco Massari, Takahiro Osawa, Naoto Miyajima, Nobuo Shinohara, Fumimasa Fukuta, Chikara Οhyama, Wataru Obara, Shinichi Yamashita, Yoshihiko Tomita, Koji Kawai, Satoshi Fukasawa, Masafumi Oyama, Junji Yonese, Masayoshi Nagata, Motohide Uemura, Kazuo Nishimura, Mutsushi Kawakita, Hiroyuki Tsunemori, Katsuyoshi Hashine, Junichi Inokuchi, Akira Yokomizo, Satoshi Nagamori and 46 more - The Lancet Oncology 2019 cited by 85

  23. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

    Authors: Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott - Clinical Cancer Research 2021 cited by 56

  24. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.

    Authors: María T. Bourlon, Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B. Apolo, Amishi Y. Shah, Camillo Porta, Cristina Suárez, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Fong Wang, Peter Wang, Julie Panzica, Viktor Fedorov, Robert J. Motzer, Toni K. Choueiri - Journal of Clinical Oncology 2024 cited by 27